Health Technology Assessment (Mar 2006)

Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation

  • C Main,
  • L Bojke,
  • S Griffin,
  • G Norman,
  • M Barbieri,
  • L Mather,
  • D Stark,
  • S Palmer,
  • R Riemsma

DOI
https://doi.org/10.3310/hta10090
Journal volume & issue
Vol. 10, no. 9

Abstract

Read online

No abstracts available.